1. Home
  2. CAPR vs ARTNA Comparison

CAPR vs ARTNA Comparison

Compare CAPR & ARTNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CAPR
  • ARTNA
  • Stock Information
  • Founded
  • CAPR 2005
  • ARTNA 1905
  • Country
  • CAPR United States
  • ARTNA United States
  • Employees
  • CAPR N/A
  • ARTNA N/A
  • Industry
  • CAPR Biotechnology: Biological Products (No Diagnostic Substances)
  • ARTNA Water Supply
  • Sector
  • CAPR Health Care
  • ARTNA Utilities
  • Exchange
  • CAPR Nasdaq
  • ARTNA Nasdaq
  • Market Cap
  • CAPR 322.7M
  • ARTNA 345.3M
  • IPO Year
  • CAPR N/A
  • ARTNA 1996
  • Fundamental
  • Price
  • CAPR $8.44
  • ARTNA $33.27
  • Analyst Decision
  • CAPR Strong Buy
  • ARTNA
  • Analyst Count
  • CAPR 8
  • ARTNA 0
  • Target Price
  • CAPR $24.75
  • ARTNA N/A
  • AVG Volume (30 Days)
  • CAPR 2.7M
  • ARTNA 27.7K
  • Earning Date
  • CAPR 08-06-2025
  • ARTNA 08-08-2025
  • Dividend Yield
  • CAPR N/A
  • ARTNA 3.79%
  • EPS Growth
  • CAPR N/A
  • ARTNA 22.05
  • EPS
  • CAPR N/A
  • ARTNA 2.08
  • Revenue
  • CAPR $17,363,588.00
  • ARTNA $109,294,000.00
  • Revenue This Year
  • CAPR $453.92
  • ARTNA $7.82
  • Revenue Next Year
  • CAPR N/A
  • ARTNA $3.54
  • P/E Ratio
  • CAPR N/A
  • ARTNA $15.59
  • Revenue Growth
  • CAPR N/A
  • ARTNA 8.31
  • 52 Week Low
  • CAPR $3.52
  • ARTNA $29.45
  • 52 Week High
  • CAPR $23.40
  • ARTNA $39.89
  • Technical
  • Relative Strength Index (RSI)
  • CAPR 38.63
  • ARTNA 38.19
  • Support Level
  • CAPR $6.26
  • ARTNA $32.29
  • Resistance Level
  • CAPR $7.28
  • ARTNA $33.60
  • Average True Range (ATR)
  • CAPR 0.69
  • ARTNA 0.55
  • MACD
  • CAPR -0.04
  • ARTNA -0.11
  • Stochastic Oscillator
  • CAPR 10.28
  • ARTNA 11.00

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

About ARTNA Artesian Resources Corporation

Artesian Resources Corp operates as a holding company with a focus on water distribution and wastewater services. Its regulated utility segment includes subsidiaries providing water and wastewater services in Delaware, Maryland, and Pennsylvania. Water distribution spans residential, commercial, industrial, and municipal sectors, while wastewater services are offered in Sussex County, Delaware. The company also engages in non-utility businesses, offering service line protection plans, engineering services, and contract operations for water and wastewater systems. The regulated utility segment constitutes the portion of the company's operations, subject to regulations by Delaware, Maryland, and Pennsylvania.

Share on Social Networks: